Start with records
Diagnosis, history, current care, relevant imaging or tests, and patient goals come before a product discussion.
Explain the rationale
Every proposed route or product should have a plain-language purpose, documented limitations, and alternatives.
Screen honestly
Some people need further testing, specialist care, or a different pathway instead of a regenerative-medicine visit.
Plan continuity
Travel, recovery, warning symptoms, and follow-up should be clear before a patient makes arrangements.
Decision guides for patients and families
Educational content only. It supports—not replaces—individual medical advice and established specialist care.
Stem Cells, Exosomes & Combined Protocols
How We Discuss MSC Therapy vs Exosome Therapy
A patient-first explanation of the questions that shape an MSC, exosome, combined-protocol, or no-treatment discussion.
Read the guideStem Cell Therapy
Why Wharton’s Jelly MSCs May Be Considered in Our Protocol Discussions
What Wharton’s jelly MSCs are, what product-source questions matter, and why source alone never determines suitability.
Read the guideStem Cell Therapy
What Viability, Sterility & Lab Reports Mean for Patients
A practical guide to reading cell-product release information, asking better questions, and understanding what lab reporting can and cannot prove.
Read the guideNeurological Conditions
When Neurological Cases Need an Intrathecal vs IV-Led Discussion
Why delivery route is a clinical question in neurological cases, what records matter, and why no route should be assumed before review.
Read the guideAutoimmune Conditions
Autoimmune Follow-up: What We Plan to Review at 3, 6 & 12 Months
A cautious, practical view of follow-up after an autoimmune regenerative-medicine consultation, including what monitoring can and cannot show.
Read the guideAnti-Aging & Wellness
Why Some Healthy-Ageing Candidates Are Accepted—and Others Are Redirected
How a responsible healthy-ageing conversation separates wellness goals from medical risk, missing information, and care that belongs elsewhere.
Read the guideOrthopaedics
MSC therapy before knee replacement
For some patients with moderate knee osteoarthritis it is a defensible step; for advanced bone-on-bone disease it usually is not. Here is how the line is drawn.
Read the guideNeurology
Parkinson's: what MSC therapy can and cannot do
Parkinson's attracts more overclaiming than almost any other indication. This page separates what is under study from what is being sold.
Read the guideNeurology
MS: MSC therapy versus HSCT
These are two very different interventions with very different evidence bases, risks and eligibility rules. Confusing them is the most common mistake we see.
Read the guidePaediatric neurology
Autism: a family decision framework
Autism is where marketing pressure on families is heaviest. This framework is written to help you say no as easily as yes.
Read the guideRespiratory
COPD and pulmonary fibrosis candidacy
Lung indications need spirometry, imaging and an honest conversation about what an infusion can plausibly change.
Read the guideMetabolic medicine
Type 2 diabetes and metabolic candidacy
There is real randomised human data here, and also a large gap between what it shows and what is advertised.
Read the guideRelated clinical questions
Where this page sits in the wider picture.